Laminin-R Antibody (MLuC5): sc-59732

Laminin-R Antibody (MLuC5) is a mouse monoclonal IgM antibody that detects Laminin-R in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Laminin-R, also known as colon carcinoma laminin-binding protein, plays a crucial role in cell adhesion and migration, which are essential processes in tissue development and repair, as well as in cancer metastasis. Laminin-R is characterized by its heterodimeric structure, which is similar to that of other extracellular matrix protein receptors, such as fibronectin and vitronectin. The incorporation of Laminin-R into lysosomal membranes facilitates the attachment of lysosomes to surfaces coated with laminin, highlighting Laminin-R′s importance in cellular interactions and signaling pathways. Notably, Laminin-R expression is significantly upregulated in aggressive carcinomas, particularly in colon cancer, where Laminin-R is found at nine-fold higher levels compared to adjacent normal colonic epithelium. This upregulation suggests that Laminin-R may serve as a potential biomarker for cancer progression and a target for therapeutic intervention. Additionally, the precursor of Laminin-R, identified as p40 ribosome-associated protein, is involved in the translational machinery, further underscoring Laminin-R′s multifunctional nature in cellular processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Laminin-R Antibody (MLuC5) References:

1. Carbohydrate-binding protein 35 is the major cell-surface laminin-binding protein in colon carcinoma.  |  Lee, EC., et al. 1991. Arch Surg. 126: 1498-502. PMID: 1842179
2. Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160.  |  Perrin, A., et al. 2017. Mol Ther Nucleic Acids. 6: 68-79. PMID: 28325301
3. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.  |  Rodrigo, GJ., et al. 2017. Int J Chron Obstruct Pulmon Dis. 12: 907-922. PMID: 28360514
4. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.  |  Rogliani, P., et al. 2018. Int J Chron Obstruct Pulmon Dis. 13: 3115-3130. PMID: 30323582
5. Single Inhaler LABA/LAMA for COPD.  |  Malerba, M., et al. 2019. Front Pharmacol. 10: 390. PMID: 31105560
6. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management.  |  Kaplan, A., et al. 2020. NPJ Prim Care Respir Med. 30: 50. PMID: 33177503
7. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.  |  Fukuda, N., et al. 2023. Cochrane Database Syst Rev. 6: CD012066. PMID: 37276335
8. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.  |  Boulet, LP., et al. 2024. J Allergy Clin Immunol Pract. 12: 1244-1253.e8. PMID: 38309696
9. LAMA improves tissue oxygenation more than LABA in patients with COPD.  |  Perez-Bogerd, S., et al. 2024. J Appl Physiol (1985). 137: 154-165. PMID: 38722752
10. Adding a LABA or LAMA to Current ICS Therapy for Uncontrolled Asthma.  |  Fletke, KJ. and Trasybule, N. 2024. Am Fam Physician. 110: 346-347. PMID: 39418565

The preferred Laminin-R antibody is Laminin-R Antibody (H-2): sc-74515.